Gut Liver.
2022 May;16(3):489-492. 10.5009/gnl210499.
High Real-World Sustained Virologic Response Rate with Glecaprevir/Pibrentasvir at a Racially Diverse Urban Academic Medical Center
- Affiliations
-
- 1Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA.
- 2University of Illinois Hospital and Health Sciences System, Chicago, IL, USA.
- 3Department of Gastroenterology and Hepatology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA.
- 4Pakistan Kidney and Liver Institute and Research Center, Lahore, Pakistan.
- KMID: 2529858
- DOI: http://doi.org/10.5009/gnl210499
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
- Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
- Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
- Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
